Demographic, clinical baseline and target lesion characteristics
| Characteristics | Elutax (n=8) | Wingspan (n=11) | P value |
| Gender, female, n (%) | 3 (38%) | 6 (55%) | 0.47 |
| Age (years), median (IQR) | 68.5 (52–76) | 67 (59–73) | 0.86 |
| Clinical follow-up (months), median (IQR) | 9.5 (4.5–27) | 10 (6–58) | 0.36 |
| NIHSS score on admission, median (IQR) | 0 (0–4) | 2 (0–6) | 0.28 |
| Vascular risk factors | |||
| Hypertension, n (%) | 6 (75%) | 8 (73%) | 0.81 |
| Diabetes, n (%) | 1 (13%) | 4 (36%) | 0.26 |
| Dyslipidemia, n (%) | 3 (38%) | 7 (64%) | 0.28 |
| Coronary artery disease, n (%) | 4 (50%) | 3 (27%) | 0.53 |
| Smoking, n (%) | 1 (13%) | 2 (18%) | 0.74 |
| Peripheral artery occlusive disease, n (%) | 0 (0%) | 1 (9%) | 0.39 |
| Atrial fibrillation, n (%) | 1 (13%) | 1 (9%) | 0.82 |
| History of stroke, n (%) | 3 (38%) | 4 (36%) | 0.96 |
| Medication on admission | |||
| Aspirin, n (%) | 3 (38%) | 7 (64%) | 0.27 |
| P2Y12 inhibitor, n (%) | 1 (13%) | 1 (9%) | 0.82 |
| Dipyridamole, n (%) | 0 | 1 (9%) | 0.39 |
| Dual antiplatelet therapy, n (%) | 1 (13%) | 1 (9%) | 0.81 |
| Vitamin K antagonist, n (%) | 1 (13%) | 0 (0%) | 0.24 |
| NOAC, n (%) | 1 (13%) | 0 (0%) | 0.24 |
| Anti-lipid agent, n (%) | 6 (75%) | 6 (55%) | 0.51 |
| Severity of stenosis | |||
| Degree of stenosis (%) before intervention, median (IQR) | 81% (72.5–92.5) | 80% (72–100) | 0.87 |
| Degree of stenosis (%) after intervention, median (IQR) | 37.5% (20–60) | 10% (10–50) | 0.23 |
| Localization of target lesions | |||
| Internal carotid artery, n (%) | 0 (0%) | 1 (9%) | 0.39 |
| Middle cerebral artery, n (%) | 3 (38%) | 5 (45%) | 0.74 |
| Vertebral artery, n (%) | 3 (38%) | 3 (27%) | 0.64 |
| Basilar artery, n (%) | 2 (25%) | 2 (18%) | 0.73 |
IQR, Interquartile range; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; NOAC, novel oral anticoagulant.